Trial · NCT03118739
Registered outcomes41
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 20 of 41
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Urinary Albumin to Creatinine Ratio (UACR) | From Baseline to 12 Weeks of Treatment | LS Mean Percentage Change (95% CI) from Baseline in UACR |
| Primary | Urinary Albumin to Creatinine Ratio (UACR) Compared to Placebo | From Baseline to 24 Weeks of Treatment | LS Mean Percentage Change (90% CI) from Baseline in UACR Compared to Placebo |
| Primary | Urinary Albumin to Creatinine Ratio (UACR) | From Baseline to 24 Weeks of Treatment | LS Mean Percentage Change (95% CI) from Baseline in UACR |
| Secondary | sUA | From Baseline to 12 Weeks and 24 Weeks of Treatment | LS Mean Percentage Change (95% CI) from Baseline in sUA |
| Secondary | eGFR | From Baseline to 12 Weeks and 24 Weeks of Treatment | LS Mean Percentage Change (95% CI) from Baseline in eGFR |
| Secondary | Serum Creatinine | From Baseline to 12 Weeks and 24 Weeks of Treatment | LS Mean Percentage Change (95% CI) from Baseline in Serum Creatinine |
| Secondary | Serum Cystatin C | From Baseline to 12 Weeks and 24 Weeks of Treatment | LS Mean Percentage Change (95% CI) from Baseline in Serum Cystatin C |
| Secondary | Serum High Sensitivity C-reactive Protein | From Baseline to 12 Weeks and 24 Weeks of Treatment | LS Mean Percentage Change (95% CI) from Baseline in Serum High Sensitivity C-reactive Protein |
| Secondary | Clinical Assessments | From Baseline to 12 Weeks and 24 Weeks of Treatment | Change from Baseline in Diastolic and Systolic Blood Pressure |
| Secondary | MRI Variables - LV Mass/End-diastolic Volume | From Baseline to 24 Weeks of Treatment | Change from Baseline in MRI Variables at Week 24 (CFB = Change from Baseline) |
| Secondary | MRI Variables - Kidney Cortex T2 Star - BOLD MRI | From Baseline to 24 Weeks of Treatment | Change from Baseline in MRI Variables at Week 24 (CFB = Change from Baseline) |
| Secondary | MRI Variables - LV End-diastolic Volume, LV End-systolic Volume, LV Stroke Volume | From Baseline to 24 Weeks of Treatment | Change from Baseline in MRI Variables at Week 24 (CFB = Change from Baseline) |
| Secondary | MRI Variables - LV Ejection Fraction, Circumferential Strain, Longitudinal Strain, Radial Strain | From Baseline to 24 Weeks of Treatment | Change from baseline in MRI Variables at Week 24 (CFB = Change from Baseline) |
| Secondary | MRI Variables - Diastolic Circumferential Strain Rate, Longitudinal Strain Rate, Radial Strain Rate and Systolic Circumferential Strain Rate, Longitudinal Strain Rate, Radial Strain Rate | From Baseline to 24 Weeks of Treatment | Change from Baseline in MRI Variables at Week 24 (CFB = Change from Baseline) |
| Secondary | MRI Variables - LV Mass | From Baseline to 24 Weeks of Treatment | Change from Baseline in MRI Variables at Week 24 (CFB = Change from Baseline) |
| Other | Flow Mediated Dilatation (Reactive Hyperemia) | From Baseline to 12 Weeks and 24 Weeks of Treatment | LS Mean Change (95% CI) from Baseline in Flow Mediated Dilatation. The flow mediated dilatation metric is obtained using a device from Cordex, and a proprietary algorithm. This metric represents the volume difference between a baseline arterial compliance curve and hyperemia arterial compliance curve in the positive transmural pressure region. This metric has a direct relationship to a subject's cardiovascular condition. Output range is 0-150. A higher score is indicative of a better flow mediated dilatation. |
| Other | Urinalysis | From Baseline to 12 Weeks and 24 Weeks of Treatment | Changes in Urinalysis (CFB = Change from Baseline) |
| Other | Clinical Chemistry Values | From Baseline to 12 Weeks and 24 Weeks of Treatment | Changes in Clinical Chemistry Values (CFB = Change for Baseline) |
| Other | Baseline eGFR | Baseline | |
| Other | Baseline UACR | Baseline |
Source ClinicalTrials.govtrials-2026-11-12-0.4.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNone stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03118739/registered